Beyond Methotrexate and Biologics in RA – Efficacy of JAK Inhibitors and their Place in the Current Treatment Armamentarium

Mediterranean Journal of Rheumatology

ARTICLE

Katerina Chatzidionysiou¹ 

[1] Department of Medicine, Karolinska Institutet, Rheumatology Unit, Karolinska University Hospital

关键词: JAK inhibitors;    methotrexate;    biologics;    treatment;    rheumatoid arthritis;   

DOI  :  10.31138/mjr.31.1.120

学科分类：社会科学、人文和艺术（综合）

来源: PCO Convin S.A.

【 摘 要 】

Treatment of rheumatoid arthritis (RA) has transformed dramatically during the last decades. A substantially revised treatment paradigm, comprising treat-to-target strategies, earlier initiation of treatment and the development and introduction to clinical practice of immune-targeted therapeutics based upon pathogenesis driven principles, has contributed to this dramatic progress.1 New and highly effective disease modifying anti-rheumatic drugs (DMARDs) are introduced as soon as possible after diagnosis is confirmed in order to inhibit radiographic progression due to irreversible joint damage that causes functional disability, chronic pain, early unemployment, and poor quality of life. Today, many conventional synthetic DMARDs (csDMARDs) and biologic DMARDs (bDMARDs) are available with distinct mechanisms of action.

【 授权许可】

CC BY-NC